Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDIV × pembrolizumab × Gastrointestinal × Clear all

Status

Sponsor Class

INDUSTRY 179 OTHER 171 NIH 10 NETWORK 2 OTHER_GOV 1 INDIV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1 Genitourinary 1 Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Adenocarcinoma 1

Interventions

Proflavine 3 sargramostim 1 pembrolizumab 1 Uracil 1 Tegafur 1 Sodium Chloride 1 Ipilimumab 1 Everolimus 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03695835 2020-07-22

NIRPA

Gary Onik MD

GastrointestinalGenitourinaryThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡